ACRS
Income statement / Annual
Last year (2023), Aclaris Therapeutics, Inc.'s total revenue was $31.25 M,
an increase of 5.03% from the previous year.
In 2023, Aclaris Therapeutics, Inc.'s net income was -$88.48 M.
See Aclaris Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$31.25 M
|
$29.75 M
|
$6.76 M
|
$6.48 M
|
$4.23 M
|
$10.09 M
|
$1.68 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$18.08 M |
$11.96 M |
$4.71 M |
$5.13 M |
$4.06 M |
$6.85 M |
$1.21 M |
$120,000.00 |
$90,000.00 |
$0.00 |
| Gross Profit |
$13.17 M |
$17.79 M |
$2.05 M |
$1.35 M |
$172,000.00 |
$3.24 M |
$476,000.00 |
-$120,000.00 |
-$90,000.00 |
$0.00 |
| Gross Profit Ratio |
0.42 |
0.6 |
0.3 |
0.21 |
0.04 |
0.32 |
0.28 |
0 |
0 |
0 |
| Research and Development
Expenses |
$98.38 M
|
$77.81 M
|
$43.81 M
|
$31.73 M
|
$64.90 M
|
$63.01 M
|
$39.79 M
|
$33.48 M
|
$15.34 M
|
$6.51 M
|
| General & Administrative
Expenses |
$31.10 M
|
$25.13 M
|
$23.62 M
|
$20.53 M
|
$27.16 M
|
$27.65 M
|
$33.11 M
|
$15.09 M
|
$5.33 M
|
$2.03 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$283,000.00
|
$671,000.00
|
$48.00 M
|
$85,000.00
|
$3.30 M
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$31.10 M
|
$25.13 M
|
$23.62 M
|
$20.53 M
|
$27.83 M
|
$75.65 M
|
$33.11 M
|
$15.09 M
|
$5.33 M
|
$2.03 M
|
| Other Expenses |
$0.00 |
$2.95 M |
-$1.14 M |
-$424,000.00 |
-$2.48 M |
$2.68 M |
$2.07 M |
$488,000.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$110.53 M |
$102.95 M |
$67.43 M |
$52.26 M |
$92.73 M |
$138.66 M |
$72.90 M |
$48.57 M |
$20.67 M |
$8.53 M |
| Cost And Expenses |
$128.61 M |
$114.91 M |
$72.15 M |
$57.39 M |
$96.78 M |
$145.51 M |
$74.11 M |
$48.57 M |
$20.67 M |
$8.53 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$104,000.00 |
$16,000.00 |
| Interest Expense |
$0.00 |
$4.70 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$863,000.00
|
$797,000.00
|
$923,000.00
|
$1.32 M
|
$1.59 M
|
$1.32 M
|
$402,000.00
|
$120,000.00
|
$90,000.00
|
$12,000.00
|
| EBITDA |
-$117.57 M
|
-$84.36 M
|
-$65.06 M
|
-$48.20 M
|
-$90.84 M
|
-$80.78 M
|
-$53.45 M
|
-$48.57 M
|
-$20.67 M
|
-$8.52 M
|
| EBITDA Ratio |
-3.76 |
-2.68 |
-6.07 |
-7.85 |
-17.52 |
-13.42 |
-43.03 |
0 |
0 |
0 |
| Operating Income Ratio
|
-3.12
|
-2.86
|
-9.67
|
-7.85
|
-26.27
|
-13.42
|
-43.03
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$8.51 M
|
$2.95 M
|
-$1.14 M
|
-$424,000.00
|
-$2.48 M
|
$2.68 M
|
-$15.99 M
|
$488,000.00
|
$104,000.00
|
$16,000.00
|
| Income Before Tax |
-$88.85 M |
-$86.91 M |
-$90.87 M |
-$51.34 M |
-$113.54 M |
-$132.74 M |
-$70.35 M |
-$48.08 M |
-$20.56 M |
-$8.52 M |
| Income Before Tax Ratio
|
-2.84
|
-2.92
|
-13.44
|
-7.92
|
-26.86
|
-13.15
|
-41.8
|
0
|
0
|
0
|
| Income Tax Expense |
-$367,000.00 |
$1.75 M |
$23.42 M |
-$182,000.00 |
$29.31 M |
$2.68 M |
-$1.83 M |
-$120,000.00 |
-$90,000.00 |
$0.00 |
| Net Income |
-$88.48 M |
-$88.66 M |
-$114.28 M |
-$51.15 M |
-$142.85 M |
-$132.74 M |
-$68.52 M |
-$48.08 M |
-$20.56 M |
-$8.52 M |
| Net Income Ratio |
-2.83 |
-2.98 |
-16.9 |
-7.89 |
-33.79 |
-13.15 |
-40.71 |
0 |
0 |
0 |
| EPS |
-1.27 |
-1.36 |
-2.01 |
-1.2 |
-3.46 |
-4.03 |
-2.44 |
-2.25 |
-3.37 |
-0.8 |
| EPS Diluted |
-1.27 |
-1.36 |
-2.01 |
-1.2 |
-3.46 |
-4.03 |
-2.44 |
-2.25 |
-3.37 |
-0.8 |
| Weighted Average Shares
Out |
$69.81 M
|
$65.21 M
|
$56.73 M
|
$42.54 M
|
$41.32 M
|
$32.91 M
|
$28.10 M
|
$21.42 M
|
$6.11 M
|
$10.66 M
|
| Weighted Average Shares
Out Diluted |
$69.81 M
|
$65.21 M
|
$56.73 M
|
$42.54 M
|
$41.32 M
|
$32.91 M
|
$28.10 M
|
$21.42 M
|
$6.11 M
|
$10.66 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
